Deescalating Adjuvant Trastuzumab in HER2-Positive Early-Stage Breast Cancer: A Systemic Review and Meta-Analysis

JNCI Cancer Spectrum
Hadar GoldvaserEitan Amir

Abstract

One year of adjuvant trastuzumab in combination with chemotherapy is the standard of care in early-stage human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Existing data on shortening trastuzumab treatment show conflicting results. A search of PubMed and abstracts from key conferences identified randomized trials that compared abbreviated trastuzumab therapy to 1 year of treatment in early-stage HER2-positive breast cancer. Hazard ratios (HRs) and 95% confidence intervals (CIs) were extracted for disease-free survival (DFS) and overall survival (OS). Subgroup analyses evaluated the effect of nodal involvement, estrogen receptor expression, and the duration of abbreviated trastuzumab (9-12 weeks vs 6 months). Odds ratios (ORs) and 95% confidence intervals were computed for prespecified cardiotoxicity events including cardiac dysfunction and congestive heart failure. P values were two-sided. Analysis included six trials comprising 11 603 patients. Shorter trastuzumab treatment was associated with worse DFS (HR = 1.14, 95% CI = 1.05 to 1.25, P  = .002) and OS (HR = 1.15, 95% CI = 1.02 to 1.29. P = .02). The effect on DFS was not influenced by estrogen receptor status (P for the subgroup difference = .23), noda...Continue Reading

References

Mar 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrew SeidmanDeborah Keefe
Apr 30, 2004·Statistics in Medicine·Michael J SweetingPaul C Lambert
Feb 24, 2006·The New England Journal of Medicine·Heikki JoensuuUNKNOWN FinHer Study Investigators
Feb 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Allison W KurianAlan M Garber
Nov 4, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Heikki JoensuuPirkko-Liisa Kellokumpu-Lehtinen
Oct 14, 2011·The New England Journal of Medicine·Dennis SlamonUNKNOWN Breast Cancer International Research Group
Oct 1, 2013·The Breast : Official Journal of the European Society of Mastology·Ana Catarina PintoMartine Piccart-Gebhart
May 16, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A KramarX Pivot
Jun 11, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Evandro de AzambujaThomas M Suter
Oct 22, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Edith A PerezNorman Wolmark
Jan 8, 2015·The New England Journal of Medicine·Sara M TolaneyEric P Winer
May 4, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D MavroudisUNKNOWN Breast Cancer Investigators of Hellenic Oncology Research Group (HORG), Athens, Greece
Jun 24, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ciara C O'SullivanRichard D Gelber
Jul 15, 2015·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Xavier PivotPierre Fumoleau
Jun 21, 2016·Research Synthesis Methods·T D Stanley, Hristos Doucouliagos
Nov 23, 2016·British Journal of Cancer·Helena M EarlLouise Hiller
Dec 13, 2016·Lancet·Sibylle Loibl, Luca Gianni

❮ Previous
Next ❯

Citations

Sep 17, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Masataka SawakiUNKNOWN RESPECT study group
Apr 29, 2020·Journal of the National Cancer Institute·Moira RushtonSusan Dent
Jul 12, 2020·The Oncologist·Miguel MartinUNKNOWN GEICAM Spanish Breast Cancer Group Steering Committee
Dec 10, 2020·Infectious Agents and Cancer·Franco M BuonaguroUNKNOWN and the INT-Pascale COVID-19 Crisis Unit
Feb 24, 2020·The American Journal of Cardiology·Oscar Calvillo-ArgüellesPaaladinesh Thavendiranathan
Jan 9, 2020·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J HeilM J Vrancken Peeters

❮ Previous
Next ❯

Software Mentioned

SPSS
SOLD
RevMan
PHARE
HER
Short

Related Concepts

Related Feeds

Cardiotoxicity

Cardiotoxicity refers to the muscle damage or dysfunction of heart electrophysiology caused by drug intake or due to disease complications. It is a well-known side effect of several cytotoxic drugs, especially of the anthracyclines and can lead to long term morbidity. Here is the latest research.